Franziska Eckert
YOU?
Author Swipe
View article: P12.04.A PERSONALIZED TARGETED GLIOBLASTOMA THERAPIES BY EX VIVO DRUG SCREENING: ADVANCED BRAIN TUMOR THERAPY CLINICAL TRIAL (ATTRACT)
P12.04.A PERSONALIZED TARGETED GLIOBLASTOMA THERAPIES BY EX VIVO DRUG SCREENING: ADVANCED BRAIN TUMOR THERAPY CLINICAL TRIAL (ATTRACT) Open
BACKGROUND When applied within a personalized treatment framework, targeted therapies have revolutionized the management of several solid cancers. So far, various clinical trials aiming to introduce the concept of personalized targeted the…
View article: P03.25.B CLINICAL UTILITY OF [18F]FET PET IN PATIENTS WITH CIRCUMSCRIBED ASTROCYTIC GLIOMA
P03.25.B CLINICAL UTILITY OF [18F]FET PET IN PATIENTS WITH CIRCUMSCRIBED ASTROCYTIC GLIOMA Open
BACKGROUND O-(2-[18F]fluoroethyl)-L-tyrosine ([¹⁸F]FET) PET is predominantly applied for molecular imaging of diffuse gliomas. In contrast, data on the clinical utility of [¹⁸F]FET PET in circumscribed astrocytic gliomas (CAG) remain scarc…
View article: P12.61.B PSEUDOPROGRESSION IN GLIOBLASTOMA: A LONGITUDINAL ANALYSIS OF RISK FACTORS AND SURVIVAL
P12.61.B PSEUDOPROGRESSION IN GLIOBLASTOMA: A LONGITUDINAL ANALYSIS OF RISK FACTORS AND SURVIVAL Open
BACKGROUND Pseudoprogression (PP) is a treatment-related imaging phenomenon that mimics true progression (P) after chemoradiotherapy for glioblastoma (GBM). Distinguishing between PP and P is essential to avoid premature therapy changes, y…
View article: Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers
Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers Open
View article: Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells
Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells Open
View article: The underestimated role of pioneering women in radiation oncology: lessons from the past for today’s practice
The underestimated role of pioneering women in radiation oncology: lessons from the past for today’s practice Open
Purpose The early history of radiation and radiation oncology is imprinted by innovative pioneers both in physics and clinical application. Despite the remarkable example of Marie Curie, the contributions of female physicians, physicists, …
View article: Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer Open
Background Existing prognostic models for breast cancer (BC) brain metastases (BM) overlook neurological symptoms. Thus, we explored the incidence and prognostic relevance of neurological symptoms in a real-world cohort of BC patients with…
View article: Clinical characteristics, molecular reclassification trajectories and DNA methylation patterns of long- and short-term survivors of WHO grade II and III glioma
Clinical characteristics, molecular reclassification trajectories and DNA methylation patterns of long- and short-term survivors of WHO grade II and III glioma Open
Purpose The prognosis of diffuse gliomas previously classified as “lower-grade” is heterogeneous and complicates clinical decisions. We aimed to investigate the molecular profile of clinical outliers to gain insight into biological drivers…
View article: Myxoid liposarcoma: treatment outcomes, metastatic pattern and volumetric analysis
Myxoid liposarcoma: treatment outcomes, metastatic pattern and volumetric analysis Open
Background Myxoid liposarcoma (MLPS) is a rare subtype of soft tissue sarcoma. This entity has a specific clinical behavior, characterized with a distinct pattern of hematogenous spread, as well as with a unique radiosensitivity and chemos…
View article: Development of an MR-only radiotherapy treatment planning workflow using a commercial synthetic CT generator for brain and head & neck tumor patients
Development of an MR-only radiotherapy treatment planning workflow using a commercial synthetic CT generator for brain and head & neck tumor patients Open
MR-only RT planning using MRCAT software package was feasible for brain and HN tumors, with acceptable clinical accuracy. The MR-invisible immobilization devices could be modelled in the planning system and the autosegmentation on sCTs usi…
View article: Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma
Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma Open
Purpose High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expressi…
View article: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers
The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers Open
Purpose The management of soft tissue sarcoma (STS) at reference centers with specialized multidisciplinary tumor boards (MTB) improves patient survival. The German Cancer Society (DKG) certifies sarcoma centers in German-speaking countrie…
View article: Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method
Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method Open
View article: Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT)
Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT) Open
Background Novel approaches to guide personalized treatment in glioblastoma are urgently needed. Given the poor predictive value of genetic biomarkers in glioblastoma, we are conducting a prospective clinical trial to investigate the novel…
View article: <scp> <i>SKA1</i> </scp> promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy
<span> <i>SKA1</i> </span> promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy Open
Oral squamous cell carcinoma (OSCC) is a malignancy associated with high morbidity and mortality, yet treatment options are limited. In addition to genetic alterations, aberrant gene expression contributes to the pathology of malignant dis…
View article: Acute remote ischemic conditioning enhances (CD3+)- but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model
Acute remote ischemic conditioning enhances (CD3+)- but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model Open
Introduction Hypoxia can drive tumor progression, suppress anti-tumor immunity, and reduce the effectiveness of radiotherapy and chemotherapy. This study aimed to assess the impact of remote ischemic conditioning (RIC) on tumor oxygenation…
View article: Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens Open
Background Diffuse hemispheric glioma, H3 G34R/V-mutant (DHG-H3G34) is characterized by poor prognosis and lack of effective treatment options. DHG-H3G34R further harbor deactivation of alpha-thalassemia/mental retardation syndrome X-linke…
View article: Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (HER2+ cohort)
View article: Supplementary Figure S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Selected CpG sites covering the genomic locus of HER3 (ERBB3) were evaluated for their methylation state (A).
View article: Supplementary Table S5 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S5 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (TNBC cohort)
View article: Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Further evaluation of HER3 expression in BM of breast and lung cancer.
View article: Supplementary Table S6 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S6 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Pathway enrichment analysis of genes associated with differentially methylated CpG sites in HER3+ vs. HER3-
View article: Supplementary Figure S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S4 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Selected CpG sites covering the genomic locus of HER3 (ERBB3) were evaluated for their methylation state (A).
View article: Supplementary Table S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S2 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Baseline characteristics of patients used for genome-wide DNA-methlyation analysis, stratified into HER3-positive and HER3-negative
View article: Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Further evaluation of HER3 expression in BM of breast and lung cancer.
View article: Supplementary Figure S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Figure S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Immune cell infiltration in BM of the three subtypes of BCa: Luminal (A), HER2-positive (B) and Triple-negative breast cancer (TNBC) (C).
View article: Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S3 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Differentially methylated CpG sites in HER3+ vs HER3- breast cancer samples (HER2+ cohort)
View article: Supplementary Table S6 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S6 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Pathway enrichment analysis of genes associated with differentially methylated CpG sites in HER3+ vs. HER3-
View article: Supplementary Table S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Protocols used for IHC stainings on the Ventana Benchmark ULTRA device
View article: Supplementary Table S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer
Supplementary Table S1 from Frequent overexpression of HER3 in brain metastases from breast and lung cancer Open
Protocols used for IHC stainings on the Ventana Benchmark ULTRA device